article thumbnail

Eli Lilly places price cap of $35 on out-of-pocket insulin cost

Pharmaceutical Technology

Eli Lilly has announced that it will reduce the price of its most commonly used insulin, Humalog, in the US, by 70% and cap the out-of-pocket cost for those on commercial insurance at $35. This is the second time Lilly has significantly reduced the cost of its insulin, as in 2019 the company reduced the list price of Humalog by 50%.

Insulin 264
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.

Insulin 328
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Insulin prices demonstrate pharma’s greed

World of DTC Marketing

WHAT’S HAPPENING: In the Build Back Better bill , Democrats are actually proposing limiting insulin prices to $35 a month but Republicans can’t have any of that. PhRMA spent pharma’s money well and bought some politicians while people who need insulin are suffering.

Insulin 184
article thumbnail

Novo Nordisk to reduce US list prices of insulin products

Pharmaceutical Technology

Novo Nordisk has announced plans to reduce the US wholesale acquisition cost (WAC), also known as the list price, of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes. Novo Nordisk also has various long-standing US affordability offerings for eligible people who are living with diabetes.

Insulin 147
article thumbnail

Biocon continues to divest with $150M sale of insulin and other brands to Eris

Fierce Pharma

Biocon and Eris have expanded a previous agreement, with Biocon selling Indian branded formulations businesses to Mumbai-based Eris for $150M.

article thumbnail

Novo Nordisk follows Lilly in sharply cutting price of insulin drugs

Bio Pharma Dive

Responding to policy changes and pressure over high drug costs, the pharma is reducing the sticker price of four branded diabetes medicines by up to 75%.

Insulin 278
article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

In addition, market growth will be driven by dapagliflozin (Farxiga) in the SGLT-2I space, and novel GLP-1/GIP Mounjaro (tirzepatide), biosimilar/interchangeable insulins such as insulin lispro and insulin glargine (Basaglar), and the launch of once-weekly insulins icodec and Icosema, forecast for 2024 launch.

Insulin 130